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ABSTRACT 
Background/Aim: Alcohol remains one of most common cause of liver disease in India, hence the present study was undertaken to assess 
the clinical profile and treatment chart review of alcoholic liver disease (ALD) patients. 
Materials and Methods: Hospital based prospective and observational study was carried out for a period of nine months in a tertiary care 
hospital of south India.  All the patients of either gender diagnosed with ALD were enrolled in the study and patient consent was taken, the 
data related to the patients of ALD were documented in a structured patient data collection form and analyzed carefully. 
Results: ALD was mainly affected in male with age group of 41-50 years. Out of 130 patients 43.8% patients were suffered from Fatty 
Liver disease while 23.1% were suffered from Alcoholic Hepatitis and 33.1% were suffered from Cirrhosis of Liver. The secondary 
developments to ALD were portal hypertension (13.8%) followed by Ascities (10.8%) and Hepatitis (10%). The major risk factors involved 
in ALD was alcohol per se (52.3%) and, alcohol and smoking exaggerate the disease condition. The Periodic (61.5%) and regular basis 
(38.5%) of alcoholism for chronic period of time may land up with ALD. Polypharmacy is essential for the treatment of ALD as it involved 
multiple secondary developments to ALD. The patients were intervened and counselled on their individual basis for ALD consequences, and 
motivated for cessation of alcohol and smoking.  
Conclusion: The study enlightens that the early diagnosis and its beneficial outcomes that can exponentially curtail the mortality rate of 
ALD. Similarly the optimal drug therapy regimen and patient counseling may improve the patient’s quality of life.  
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INTRODUCTION 
Alcoholic liver disease (ALD) is a serious disorder and 
has deadly consequences over excessive alcohol 
consumption. Excess Alcohol ingestion is the leading 
cause of death in people aged with 15-49 years
 .
In most 
of the countries, alcohol is the most common cause of 
liver cirrhosis
 1
. Alcohol induced toxicity is the 3rd 
cause of morbidity 
2
. 
The liver is a largest and most complex organ of the 
body; it performs multiple functions in the body it may 
include, secretion of proteins and enzymes, purification 
of toxins, anabolic and catabolic functions and 
cholesterol regulation. It is primarily involved in the 
metabolism of alcohol and most susceptible for alcohol 
related injuries 
3
. 
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Alcohol is used by mankind since ancient times for 
various purposes; it includes stimulation of central 
nervous system and as an aphrodisiac. According to 
Hindu mythology, alcohol has been stated as “Somaras” 
4
. Alcohol acts as a behavioural stimulant at lower blood 
levels but at its higher level it acts as a central nervous 
system depressant. Royal college of physicians (RCP) 
advice a weekly limit of alcohol ingestion, for men it is 
21 units (210g) and 14 units for women. The liver and 
body usually cope with drinking of small amount (1-2 
units) or within prescribed limit may help to prevent 
heart disease and stroke 
5
. ALD comprises of three main 
types: Fatty liver, liver cirrhosis and Alcoholic hepatitis 
6
. Alcohol metabolism provides the origin for 
understanding alcohol-induced liver damage. Alcohol is 
metabolized in the liver and Alcohol dehydrogenase 
(ADH) is the major enzyme concerned in the 
metabolism of alcohol. This enzyme converts alcohol to 
acetaldehyde through a chemical process called 
oxidation. Even in low concentrations, Acetaldehyde is 
vastly toxic to the body. Normally however, the enzyme 
aldehyde dehydrogenase (ALDH) rapidly oxidizes 
acetaldehyde to acetate. Most of the acetate travels 
throughout the bloodstream to other parts of the body, 
where it can enter former metabolic cycles that construct 
energy or useful molecules. According to WHO, alcohol 
ingestion ranks world third largest burden disease. 
Alcohol abuse not only affects the liver, it also affects 
other organs and systems such as, gastrointestinal tract, 
pancreas, circulatory organs, cranial nerves and blood 
circulation
7
. The diagnosis of ALD is depends on 
history of alcohol ingestion, physical signs and 
symptoms, and laboratorial investigations. Hence the 
present study was undertaken for grading of alcoholic 
liver disease, assessment of risk factors involved and 
review of treatment chart for better utilization of 
medicaments in the management of ALD patients.      
MATERIALS AND METHODS 
Study design and settings: A prospective and 
observational study was conducted for a period of nine 
months in a tertiary care hospital of Shri B.M.Patil 
medical college hospital and Research centre, in 
Vijaypur, after obtaining the Institutional ethical 
Committee Clearance. The hospital provides primary 
and specialized health care facilities to people in and 
around Vijayapur district. The patients admitted to 
medicine ward was screened according to inclusion and 
exclusion criteria and 130 patients were finally selected 
for the study. 
Inclusion criteria: 
 All the patients admitted to the wide-ranging 
medicine ward. 
 Patients of each sex, of age 18-70 years. 
 In-Patients only 
 Patients with alcoholic liver disease are included. 
Exclusion criteria: 
 Pregnant and lactating women. 
 Patients who are unconscious or in coma 
 Unable to comply due to mental retardation.. 
 Non alcoholic liver diseases patients are excluded 
Source of data: Data extracted from the case files by 
using data collection form (includes demographic data, 
chief complaints, social history, side effects, past 
medical history and past medication history, laboratory 
details, diagnosis and treatment chart).  
Study procedure: All the patients of either of gender 
diagnosed with ALD by confirmed laboratory findings 
and patients willing to participate were included in the 
study. Data extracted from the case files by using data 
collection form by either interviewing or by extraction 
of data from patient’s case files or both of the above. 
The data collected from each patient has been 
documented in patient data collection form and 
analyzed.  
Sample size: 
The sample size was calculated by the following 
formula with help of statistician. 
 N   = (Z α2 x S2) / d2 
Where n= Sample size  
         Z= Level of significance 
         d
2
 = 10% absolute error 
         S
2
= Variance of a sample    
         α2 = Probability of type 1 error 
Statistical analysis: The data were expressed in simple 
mathematics and multiple responses were reported in 
terms of percentages. The graphs and tables were 
generated using the Microsoft excel sheet. 
RESULTS 
A total of 130 patients were included in the study, out of 
them all were males (Table 1). Maximum patients 
admitted to medicine department (46.2%) were from age 
group 41-50 years followed by 25.4% from age group 
30-40 years and 16.9% from age group 51-60 years.  
Table 1: Distribution of Cases According to Age: 
AGE (YRS) No. of patients Percent% 
30-40 33 25.4 
41-50 60 46.2 
51-60 22 16.9 
61-70 12 9.2 
>70 3 2.3 
Total 130 100 
 
Out of 130 patients 43.8% patients were suffered from 
Fatty Liver disease while 23.1% were suffered from 
Alcoholic Hepatitis and 33.1% were suffered from 
Cirrhosis of Liver. The secondary developments to ALD 
were portal HTN (13.8%) followed by Ascities (10.8%) 
whereas, 10% patients had Hepatitis. A significant 
number of patients also had Anaemia.  
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Out of 130 patients 57.7% patients had Mild duration of 
hospital stay and 24.6% patients had Moderate duration 
of hospital stay. It was found that out of 130 patients 
52.3% patients had alcohol as major risk factor while 
47.7% patients had alcohol and smoking risk factor. 
The results showed that out of total patient’s 67.7% 
patients had other type of alcohol than brandy or 
whisky. It was found that out of 130 patients 61.5% 
patients had alcohol periodically while 38.5% patients 
had alcohol daily. According to CAGE it was found that 
out of total 130 patients 58.5% patients had significant 
while 41.5% patients had non-significant.  Out of total 
130 patients 69.2% patients had prescribed up to 7 
medications while 30.8% patients had prescribed up to 
15medications. It shows that Vit B1, B2, B12, K was 
prescribed for treatment to 61.5%% patients followed by 
pantoprazole (53.8%), Spironolactone (42.3%) and 
cefotaxime (37.7%). Ceftriaxone, Propranolol, 
Thiamine, L-ornithine- L-asparate, were other major 
drugs which were prescribed to more than 30% patients. 
All the patients were intervened and counselled on their 
individual conditions for ALD consequences and 
motivated for cessation of alcohol and smoking. Role of 
nutritional support therapy and medication adherence 
were addressed to the patients. For the professionals it 
was recommended that, the significance of NLEM and 
its importance in patient care. 
DISCUSSION 
The percentage of male patients suffering from ALD 
was found to be 100% as all admitted patients were 
male, which is non-comparable to the study conducted 
by Vinayak S. Jamdade 
8
 where the male (96.7%) 
patients were suffering more with ALD when compared 
to female. In the present study did not get any single 
female patient of ALD, this may be due girls/females are 
still follows their Indian traditional culture that too 
especially in non-metro cities.   
In the present study, maximum number of patients were 
60(42.6%) of ALD with the age group of 41-50, 
followed by the patients 30-40 is 33(25.4) which is 
related to the study conducted by Vinayak S. Jamdade
 8
 
which showed that the patients (34.74%) with the age 
group of  31-40 years were mainly affected. These age 
group people are more likely to be affected due to 
excessive alcohol consumption as ALD requires years 
together to show its progressiveness and lethal 
consequences. (Table no. 01). 
Table 2:  Distribution of Cases According to Types of 
Alcoholic Liver Disease 
Types of Alcoholic Liver 
Disease 
No. of 
patients Percent % 
Alcoholic Hepatitis 30 23.1 
Cirrhosis of Liver 43 33.1 
Fatty Liver 57 43.8 
Total 130 100 
 
In the present study it is analysed that more number of 
patients affected with Fatty liver were 57 (43.8%)  and   
followed by Liver cirrhosis 40 (33.1%). Patients were 
predominantly high with Fatty Liver as it is first stage of 
the ALD and upon immediate starts of treatment disease 
did not progressed (Table no.02). 
The secondary developments to ALD seen were portal 
hypertension (13.8%), Ascities (10.8%), hepatitis (10%) 
and anemia (6%) in most of patients. Abstinence 
improves the survival and prognosis of patients with 
ALD and prevents progression to liver cirrhosis through 
histologic development and decline in portal pressure. 
(Table no.03). 
Table 3: Secondary Developments to ALD. 
Secondary Developments 
No. of 
patients 
Percent
% 
Portal HTN 18 13.8 
Ascities 14 10.8 
Hepatitis 13 10.0 
Anemia 6 4.6 
Diabetes (Comorbid) 6 4.6 
Chronic liver disease  4 3.1 
Psychotic syndrome 4 3.1 
Hepatic coma 3 2.3 
Jaundice 3 2.3 
Alcohol withdrawal 
symptom 3 2.3 
Hepatic precoma 3 2.3 
Acute Gastritis 2 1.5 
   
Based on the length of hospital stay during the treatment 
period; it was observed that 57.7% of patients stayed for 
about 1-7 days. The patients who are admitted to the 
hospital at their initial stage of ALD did not lead to 
further severity of the disease as they have been started 
treatment (Table no.04). 
Table 4: Distribution of Cases According to Duration 
of Hospital Stay 
Duration of Hospital 
Stay 
No. of 
patients Percent% 
Mild( 1-7 days) 75 57.7 
Moderate( 8-15 days) 32 24.6 
Rigorous( 16-30 days) 23 17.7 
Total 130 100 
 
Alcohol was a major risk factor in 52.3% patients, 
followed by alcohol and smoking in 47.7%. Alcohol is 
well known to cause liver disorders because of the fact 
that healthy liver tissues are replaced with scar tissues 
that ultimately leads to improper functioning of 
liver.(Table no.05). 
 
Table 5: Distribution of Cases According to Risk Factors 
Risk Factors No. of patients Percent% 
Alcohol 68 52.3 
Alcohol & Smoking 62 47.7 
Total 130 100 
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With 130 patients 67.7% patients had other type of 
alcohol (local brands) which was predominantly high 
followed by brandy and whisky. Local brands of alcohol 
are more preferred in rural areas due to economic factor. 
(Table no.06). 
Table 6:  Distribution of Cases According to Types of 
Alcohol 
Types of Alcohol No. of patients Percent% 
BRANDY 26 20 
WHISKY 16 12.3 
OTHERS (Local Brands) 88 67.7 
Total 130 100 
 
 It was found that out of 130 patients 61.5% patients had 
alcohol periodically while 38.5% patients had alcohol 
daily may be due to addiction of alcohol consumption 
(Table no.07). 
Table 7:  Distribution of Cases According to Frequency 
Frequency No. of patients Percent% 
Daily 50 38.5 
Periodically 80 61.5 
Total 130 100 
 
Table 8: Distribution of cases according to number of 
medications 
No. of Medications No. of patients Percent% 
Up to 7 90 69.2 
Up to 15 40 30.8 
Total 130 100 
 
69.2% patients had prescribed up to 7 medications while 
30.8% patients had prescribed up to 15 medications. 
These medications are prescribed based on their 
individual health conditions of the patient (Table no.08). 
A CAGE questionnaire is the method to assess the 
clinical significance of alcohol addiction which is 
directly or indirectly involved in fast progression of 
ALD. According to CAGE questionnaire out of 130 
patients, 58.5% of patients were Clinical significant 
followed by 41.5% patients were non-significant which 
is contradictory to the study conducted by Mohannad 
Dugum
 9
 which shows non-significant patients were high 
when compared to significant (Table no.09). 
Table 9:  Distribution of Cases According to CAGE 
Questionnaire. 
CAGE No. of patients Percent% 
Significant( 2 or  >  2) 76 58.5 
Non-Significant(0 or 1) 54 41.5 
Total 130 100 
 
The primary drugs used for the alcoholic liver diseases 
are L-Ornithine-L-Aspertate, Ursodiol etc. The 
percentage of   L-Ornithine-L-Aspartate in the present 
study was (32.3%) followed by Ursodiol (18.5%). 
Prescribing pattern of drugs indicates 61.5% patients 
prescribed with Vitamin supplements and 53.8% patients 
prescribed with Pantoprazole. This clearly indicated that 
there is a tendency to prescribe vitamins, proton pump 
inhibitors, hepatoprotective agents and laxatives in ALD 
patients. The possible reason behind most frequent use 
of vitamin supplements in patients may be for quick 
recovery of liver functions. Secondly Pantoprazole was 
prescribed may be due to gastric disorder associated 
with ALD. This is related to the study conducted by 
Vinayak S Jamdade
 8
 where the pantoprazole (78.67%) 
was predominantly prescribed (Table no.10). 
Patient related recommendations - Stop alcohol intake 
immediately, Stop smoking, Adherence to medication, 
Nutritional intake on regular basis, Patient counselling 
for ALD consequences 
Physician related recommendations - Use of 
corticosteroids on conditional basis, Nutritional support, 
therapy, Use of baclofen on conditional basis, Prescribe 
the  drug from  NLEM on required basis. 
 
Table 10: Distribution of Cases According to Generic Name of Drugs Prescribed As Per NLEM. 
Sr.no Generic name Prescribed NLEM (Yes/No) No.of Patients  Percentage% 
1 Vitamin B1 ,B2,B12, K Yes 80 61.5 
2 Pantoprazole Yes 70 53.8 
3 Spironolactone Yes 55 42.3 
4 Cefotaxime Yes 49 37.7 
5 Ceftriaxone Yes 49 37.7 
6 Propranolol Yes 48 36.9 
7 Thiamine Yes 45 34.6 
8 L-ornithine- L-asparate Yes 42 32.3 
9 Furosemide Yes 33 25.4 
10 Ondansetron Yes 33 25.4 
11 Ofloxacin Yes 30 23.1 
12 Folic acid Yes 30 23.1 
13 Ursodiol Yes 24 18.5 
14 Vitamin A  Yes 20 15.4 
15 Metadoxine Yes 15 11.5 
16 Rifaximine Yes 13 10.0 
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17 Lorazepam Yes 13 10.0 
18 Albumin Yes 13 10.0 
19 Tramodol Yes 12 9.2 
20 Sucralfate Yes 11 8.5 
21 Hyoscine Butyl Bromide Yes 11 8.5 
22 Lactiol Monohydrate Yes 9 6.9 
23 Lactulose Yes 4 3.1 
24 Lactulose Yes 4 3.1 
25 Phenytoin Yes 3 2.3 
26 Hydrocortisone Yes 2 1.5 
27 Pentoxifylline Yes 1 0.8 
28 Metronidazole Yes 1 0.8 
 
Table 11: Recommendations for ALD. 
 Patient related recommendations 
   1. Stop alcohol intake immediately 
   2. Stop smoking 
   3. Adherence to medication 
   4. Nutritional intake on regular basis 
   5. Patient counselling for ALD consequences 
 Physician related recommendations 
   1. Use of corticosteroids on conditional basis. 
   2. Nutritional support therapy. 
   3. Use of Baclofen on conditional basis. 
   4.  Prescribe the drug from NLEM on required basis. 
 
CONCLUSION 
According to NLEM, Hepamerz, ursodiol was the most 
commonly prescribed liver protective’s, followed by 
Liveril excluding from NLEM but are widely prescribed 
in our hospital. In the present study it is found that 
Vitamin B1, B2, B12, and Vitamin K, pantoprozole, 
Spironolactone, vitamins, cefotaxime, ceftriaxone, 
Thiamine, L-ornithine- L-asparate, etc. are the 
commonly used medications in ALD Patients. The 
values of prescribing indicators for average number of 
drugs per encounter, generic drug, injections, and drugs 
from NELM shows, deviation from the standard 
prescribing guidelines values recommended by WHO. 
Hence more multi-centred studies are required to be 
conducted to draw the best results on prescribing pattern 
of alcoholic liver disease in India.  Therefore, these 
factors should be monitored extreme closely in order to 
ensure proper prescribing habits in the Indian hospitals. 
Bad prescribing habits often leads to ineffective and 
unsafe treatment, increases the treatment cost, increases 
the chance of adverse consequences and drug 
interactions and finally causes distress and harmful to 
the patients
 7
. So, it is necessary to promote the rational 
drug use in developing countries with the help of WHO 
drug use indicators
 10
.  Liveril (Silymarin) drug is a liver 
protective used extensively in the present study and 
proven its efficacy for ALD treatment, hence it may be 
recommended to include in the NLEM list for the better 
patient outcome. 
The present study concludes that alcoholism is the main 
culprit in the development of ALD and alcohol abuse 
plays an important role in the expansion of alcohol-
related liver damages. ALD dependent secondary 
developments were seen in most of patients such as, 
portal hypertension, asciitis and anemia. Treatment 
regimen review of the present work indicates most of 
the drugs prescribed were from the NLEM list, which 
authenticate the rationality of drug usage in the hospital 
set up. 
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